SEARCH

SEARCH BY CITATION

References

  • Aksenov M. Y. and Markesbery W. R. (2001) Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer’s disease. Neurosci. Lett. 302, 141145.
  • Anekonda T. and Reddy H. P. (2005) Can herbs provide a new generation of drugs for treating Alzheimer’s disease? Brain Res. Rev. 50, 361376.
  • ANON (2003) Health & Wellness Trends Report 2003. Natl. Marketing Inst., Harleyville, PA.
  • Arendash G. W., Jensen M. T., Salem Jr N., Hussein N., Cracchiolo J., Dickson A., Leighty R. and Potter H. (2007) A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer’s transgenic mice. Neuroscience 149, 286302.
  • Balakrishnan K., Verdile G., Mehta P. D., Beilby J., Nolan D., Galvao D. A., Newton R., Gandy S. E. and Martins R. N. (2005) Plasma Aβ1-42 correlates positively with increased body fat in healthy individuals. J. Alzheimers Dis. 8, 269282.
  • Bastianetto S., Ramassamy C., Doré S., Christen Y., Poirier J. and Quirion R. (2000) The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur. J. Neurosci. 12, 18821890.
  • Bastianetto S., Yao Z. X., Papadopoulos V. and Quirion R. (2006) Neuroprotective effects of green and black teas and their catechin gallate esters against β-amyloid-induced toxicity. Eur. J. Neurosci. 23, 5564.
  • Brookmeyer R., Gray S. and Kawas C. (1998) Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337–1342.
  • Bubber P., Haroutunian V., Fisch G., Blass J. P. and Gibson G. E. (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 57, 695703.
  • Busciglio J., Yeh J. and Yankner B. A. (1993) β-Amyloid neurotoxicity in human cortical culture is not mediated by excitotoxins. J. Neurochem. 61, 15651568.
  • Cao D., Lu H., Lewis T. L. and Li L. (2007) Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 282, 3627536282.
  • Chen J., Zhou Y., Mueller-Steiner S., Chen L. F., Kwon H., Yi S., Mucke L. and Gan L. (2005) SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 280, 4036440374.
  • Craft S. (2007) Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4, 147152.
  • Craft S. and Watson G. S. (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3, 169178.
  • Dai Q., Borenstein A. R., Wu Y., Jackson J. C. and Larson E. B. (2006) Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am. J. Med. 119, 751759.
  • Defeudis F. V. (2002) Bilobalide and neuroprotection. Pharmacol. Res. 46, 565568.
  • Dietrich M. O., Spuch C., Antequera D., Rodal I., De Yebenes J. G., Molina J. A., Bermejo F. and Carro E. (2007) Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol. Aging [Epub ahead of print].
  • Duncan A. M., Phipps W. R. and Kurzer M. S. (2003) Phyto-oestrogens. Best Pract. Res. Clin. Endocrinol. Metabol. 17, 253271.
  • Durga J., Van Boxtel M. P., Schouten E. G., Kok F. J., Jolles J., Katan M. B. and Verhoef P. (2007) Effect of 3-year folic acid supplementation on cogniyive function in older adults in the FACIT trial: a randomized,double blind, controlled trial. Lancet 369, 208216.
  • Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E. A., Frosch M., Eckman C. B., Tanzi R. E., Selkoe D. J. and Guenette S. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid-β protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100, 41624167.
  • Feinman R. D. and Volek J. S. (2006) Low carbohydrate diets improve atherogenic dyslipidemia even in the absence of weight loss. Nutr. Metab. (lond) 3, 24.
  • Fewlass D. C., Noboa K., Pi-Sunyer F. X., Johnston J. M., Yan S. D. and Tezapsidis N. (2004) Obesity-related leptin regulates Alzheimer’s Aβ. FASEB J. 18, 18701878.
  • Forette F., Seux M. L., Staessen J. A. et al. (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352, 13471351.
  • Forsythe C., Phinney S., Fernandez M. L., Quann E. E., Wood R. J., Bibus D. M., Kraemer W. J., Feinman R. D. and Volek J. S. (2008) Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids 43, 6577.
  • Freund-Levi Y., Basun H., Cederholm T. et al. (2007) Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry 23, 161169.
  • Frolich L., Blum-Degen D., Bernstein H. G. et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J. Neural. Transm. 105, 423438.
  • Gabuzda D., Busciglio J., Chen L. B., Matsudaira P. and Yankner B. A. (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 269, 1362313628.
  • Gan L. (2007) Therapeutic potential of sirtuin-activating compounds in Alzheimer’s disease. Drug News Perspect. 20, 233239.
  • Ganguli M., Chandra V., Kamboh M. et al. (2000) Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US cross-national dementia study. Arch. Neurol. 57, 824830.
  • Gardner C. D., Kiazand A., Alhassan S., Kim S., Stafford R. S., Balise R. R., Kraemer H. C. and King A. C. (2007) Comparison of the Atkins, Zone, Ornish, and LEARN Diets for change in weight and related risk factors among overweight premenopausal women. JAMA 297, 969977.
  • Gasparini L., Gouras G., Wang R., Gross R. S., Beal M. F., Greengard P. and Xu H. (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21, 25612570.
  • Grant W. B. (1999) Dietary links to Alzheimer’s disease: 1999 update. J. Alzheimers Dis. 1, 197201.
  • Gustafson D., Rothenberg E., Blennow K., Steen B. and Skoog I. (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 163, 15241528.
  • Gutierrez M., Akhavan M., Jovanovic L. and Peterson C. M. (1998) Utility of a short-term 25% carbohydrate diet on improving glycemic control in type 2 diabetes mellitus. J. Am. Coll. Nutr. 17, 595600.
  • Haass C., Koo E. H., Mellon A., Hung A. Y. and Selkoe D. J. (1992) Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500503.
  • Haley A. P., Knight-Scott J., Simnad V. I. and Manning C. A. (2006) Increased glucose concentration in the hippocampus in early Alzheimer’s disease following oral glucose ingestion. Magn. Reson. Imaging 24, 715720.
  • Hartman R. E., Shah A., Fagan A. M., Schwetye K. E., Parsadanian M., Schulman R. N., Finn M. B. and Holtzman D. M. (2006) Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 24, 506515.
  • Hashimoto M., Hossain S., Agdul H. and Shido O. (2005) Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid β-infused rats relates to the decreases of amyloid β and cholesterol levels in detergent-insoluble membrane fractions. Biochim. Biophys. Acta 1738, 9198.
  • Hayden K. M., Zandi P. P., Lyketsos C. G. et al. (2006) Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis. Assoc. Disord. 20, 93100.
  • Head E., Pop V., Vasilevko V. et al. (2008) A two-year study with fibrillar β-amyloid (Aβ) immunization in aged canines: effects on cognitive function and brain Aβ. J. Neurosci. 28, 35553566.
  • Heo H. J. and Lee C. Y. (2004) Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration. J. Agric. Food. Chem. 52, 75147517.
  • Heo H. J., Choi S. J., Choi S.-G., Shin D.-H., Lee J. M. and Lee C. Y. (2008) Effects of banana, orange, and apple on oxidative stress-induced neurotoxicity in PC12 cells. J. Food Sci. [Epub ahead of print]
  • Ho L., Qin W., Pompl P. N. et al. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 12, 902904.
  • Howes M. J., Perry N. S. and Houghton P. J. (2003) Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and other cognitive disorders. Phytother. Res. 17, 118.
  • Hoyer S. (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). J. Neural Transm. 109, 9911002.
  • Huang H. J., Liang K. C., Chen C. P., Chen C. M. and Hsieh-Li H. M. (2007) Intrahippocampal administration of A β (1-40) impairs spatial learning and memory in hyperglycemic mice. Neurobiol. Learn. Mem. 87, 483494.
  • Jagust W. J., Seab J. P., Huesman R. H., Valk P. E., Mathis C. A., Reed B. R., Coxson P. G. and Budinger T. F. (1991) Diminished glucose transport in Alzheimer’s disease: dynamic PET studies. J. Cereb. Blood Flow Metab. 11, 323330.
  • Kilander L., Nyman H., Boberg M., Hanson L. and Lithell H. (1998) Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 31, 780786.
  • Krauss R. M., Blanche P. J., Rawlings R. S., Fernstrom H. S. and Williams P. T. (2006) Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am. J. Clin. Nutr. 83, 10251031.
  • LaFerla F. M., Green K. N. and Oddo S. (2007) Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci. 8, 499509.
  • Lau F. C., Shukitt-Hale B. and Joseph J. A. (2005) The beneficial effects of fruit polyphenols on brain aging. Neurobiol. Aging 26, 128132.
  • Lau F. C., Shukitt-Hale B. and Joseph J. A. (2007) Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress. Subcell. Biochem. 42, 299318.
  • Le Bars P. L., Velasco F. M., Ferguson J. M., Dessain E. C., Kieser M. and Hoerr R. (2002) Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer’s disease. Neuropsychobiology 45, 1926.
  • Leibson C. L., Rocca W. A., Hanson V. A., Cha R., Kokmen E., O’Brien P. C. and Palumbo P. J. (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 145, 301308.
  • Li Z. G., Zhang W. and Sima A. A. (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56, 18171824.
  • Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A. and Cole G. M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 83708377.
  • Lim G. P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem Jr N., Frautschy S. A. and Cole G. M. (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 30323040.
  • Lin M. T. and Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787795.
  • Lin C. L., Chen T. F., Chiu M. J., Way T. D. and Lin J. K. (2007) Epigallocatechin gallate (EGCG) suppresses β-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3β activation. Neurobiol. Aging [Epub ahead of print]
  • Luchsinger J. A., Tang M.-X., Shea S. and Mayeux R. (2002) Calorie intake and the risk of Alzheimer disease. Arch. Neurol. 59, 12581263.
  • Luchsinger J. A., Tang M.-X., Shea S. and Mayeux R. (2004a) Hyperinsulinemia and risk of Alzheimer’s disease. Neurology 63, 11871192.
  • Luchsinger J. A., Tang M.-X., Siddiqui M., Shea S. and Mayeux R. (2004b) Alcohol intake and risk of dementia. J. Am. Geriatr. Soc. 52, 540546.
  • Luo Y., Smith J. V., Paramasivam V., Burdick A., Curry K. J., Buford J. P., Khan I., Netzer W. J., Xu H. and Butko P. (2002) Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl Acad. Sci. USA 99, 1219712202.
  • Macheix J. J., Fleuriet A. and Billot J. (1990) Fruit Phenolics. CRC Press, Inc., Boca Raton, FL, USA.
  • Maclennan K. M., Darlington C. L. and Smith P. F. (2002) The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 67, 235257.
  • Manach C., Williamson G., Morand C., Scalberg A. and Remesy C. (2005) Bioavailability and bioefficiency of polyphenols in humans: I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 81, 230S242S.
  • Mattson M. P. (2003) Will caloric restriction and folate protect against AD and PD? Neurology 60, 690695.
  • McGraw J. B. and Furedi M. A. (2005) Deer browsing and population viability of a forest understory plant. Science 307, 920922.
  • McMahon J. A., Green T. J., Skeaff C. M., Knight R. G., Mann J. I. and Willaims S. M. (2006) A controlled trial of homocysteine lowering and cognitive performance. NEJM 354, 27642772.
  • Meyer J. S., Rauch G., Rauch R. A., Haque A. and Crawford K. (2000) Cardiovascular and other risk factors for Alzheimer’s disease and vascular dementia. Ann. N.Y. Acad. Sci. USA 903, 411423.
  • Mielke M. M., Rosenberg P. B., Tschanz J. et al. (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69, 18501858.
  • Minoshima S., Frey K. A., Foster N. L. and Kuhl D. E. (1995) Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J. Comput. Assist. Tomogr. 19, 541547.
  • Morris M. C., Evans D. A., Bienias J. L., Tangney C. C., Bennett D. A., Wilson R. S., Aggarwal N. and Schneider J. (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer’s disease. Arch. Neurol. 60, 940946.
  • Nichols-Richardson S. M., Coleman M. D., Volpe J. J. and Hosig K. W. (2005) Perceived hunger is lower and weight loss is greater in overweight premenopausal women consuming a low-carbohydrate/high-protein vs high-carbohydrate/low-fat diet. J. Am. Diet. Assoc. 105, 14331437.
  • Niidome T., Takahashi K., Goto Y. et al. (2007) Mulberry leaf extract prevents amyloid β-peptide fibril formation and neurotoxicity. Neuroreport 18, 813816.
  • Nijveldt R. J., Van Nood E., Van Hoorn D. E., Boelens P. G., Van Norren K. and Van Leeuwen P. A. (2001) Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74, 418425.
  • Okello E. J., Savelev S. U. and Perry E. K. (2004) In vitro anti-β-secretase and dual anti-cholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia. Phytother. Res. 18, 624627.
  • Oken B. S., Storzbach D. M. and Kaye J. A. (1998) The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 55, 14091415.
  • Peng Q., Buz’Zard A. R. and Lau B. H. (2002) Neuroprotective effect of garlic compounds in amyloid-β peptide-induced apoptosis in vitro. Med. Sci. Monit. 8, BR328BR337.
  • Petot G. J., Traore F., Debanne S. M., Lerner A. J., Smyth K. A. and Friedland R. P. (2003) Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism 52, 279281.
  • Phiel C. J., Wilson C., Lee V. M. and Klein P. S. (2003) GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 423, 435439.
  • Picklo Sr M. J. and Montine T. J. (2007) Mitochondrial effects of lipid-derived neurotoxins. J. Alzheimers Dis. 12, 185193.
  • Pyorala M., Miettinen H., Halonen P. et al. (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middleaged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler. Thromb. Vasc. Biol. 20, 538544.
  • Qin W., Chachich M., Lane M., Roth G., Bryant M. R., Ottinger M. A., Mattison J., Ingram D., Gandy S. and Pasinetti G. M. (2006a) Calorie restriction attenuates Alzheimer’s disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J. Alzheimers Dis. 10, 417422.
  • Qin W., Yang T., Ho L. et al. (2006b) Neuronal SIRT1 activation as a novel mechanism underlying the preservation of Alzheimer’s disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 2174521754.
  • Ringman J. M., Frautschy S. A., Cole G. M., Masterman D. L. and Cummings J. L. (2005) A potential role of the curry spice curcumin in Alzheimer’s disease. Curr. Alzheimer Res. 2, 131136.
  • Rivera E. J., Goldin A., Fulmer N., Tavares R., Wands J. R. and De La Monte S. M. (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J. Alzheimer Dis. 8, 247268.
  • Russo A., Palumbo M., Aliano C., Lempereur L., Scoto G. and Renis M. (2003) Red wine micronutrients as protective agents in Alzheimer-like induced insult. Life Sci. 72, 23692379.
  • Savaskan E., Olivieri G., Meier F., Seifritz E., Wirz-Justice A. and Müller-Spahn F. (2003) Red wine ingredient resveratrol protects from β-amyloid neurotoxicity. Gerontology 49, 380383.
  • Selkoe D. J. (2001) Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J. Alzheimers Dis. 3, 7580.
  • Seshadri P., Iqbal N., Stern L., Williams M., Chicano K. L., Daily D. A., McGrory J., Gracely E. J., Rader D. J. and Samaha F. F. (2004) A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am. J. Med. 117, 398405.
  • Shishodia S., Sethi G. and Aggarwal B. B. (2005) Curcumin: getting back to the roots. Ann. N.Y. Acad. Sci. USA 1056, 206217.
  • Shoji M., Golde T. E., Ghiso J. et al. (1992) Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258, 126129.
  • Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L. A., Nilsson L., Persson G., Odén A. and Svanborg A. (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 11411145.
  • Smith M. A., Rottkamp C. A., Nunomura A., Raina A. K. and Perry G. (2000) Oxidative stress in Alzheimer’s disease. BBA 1502, 139144.
  • Steen E., Terry B. M., Rivera E. J., Cannon J. L., Neely T. R., Tavares R., Xu X. J., Wands J. R. and De La Monte S. M. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease – is this type 3 diabetes? J. Alzheimers Dis. 7, 6380.
  • Stolk R. P., Breteler M. M., Ott A., Pols H. A., Lamberts S. W., Grobbee D. E. and Hofman A. (1997) Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care 20, 792795.
  • Taniguchi C. M., Emanuelli B. and Kahn C. R. (2006) Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 8596.
  • Tomlinson D. R. and Gardiner N. J. (2008) Glucose neurotoxicity. Nat. Rev. Neurosci. 9, 3645.
  • Torpy J. M., Lynm C. and Glass R. M. (2006) JAMA patient page. The metabolic syndrome. JAMA 295, 850.
  • Vassar R. and Citron M. (2000) Aβ-generating enzymes: recent advances in β- and gammasecretase research. Neuron 27, 419422.
  • Vina J., Lloret A., Valles S. L., Borras C., Badia M. C., Pallardo F. V., Sastre J. and Alonso M. D. (2007) Effect of gender on mitochondrial toxicity of Alzheimer’s Aβ peptide. Antioxid. Redox Signal. 9, 16771690.
  • Volek J. S. and Feinman R. D. (2005) Carbohydrate restriction improves the features of metabolic syndrome. Metabolic syndrome may be defined by the response to carbohydrate restriction. Nutr. Metab. (Lond) 2, 31.
  • Wang J., Ho L., Qin W. et al. (2005) Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer’s disease. FASEB J. 19, 659661.
  • Wang J., Zhao Z., Ho L., Seror I., Humala N., Percival S. and Pasinetti G. M. (2006) Moderate consumption of Cabernet Sauvignon attenuates β-amyloid neuropathology in a mouse model of Alzheimer’s disease. FASEB J. 20, 23132320.
  • Westman E. C., Yancy Jr W. S., Olsen M. K., Dudley T. and Guyton J. R. (2006) Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int. J. Cardiol. 110, 212216.
  • Whitmer R. A. (2007) The epidemiology of adiposity and dementia. Curr. Alzheimer Res. 4, 117122.
  • Williams R. J. and Spencer J. P. (2004) Rice-Evans C. Flavonoids: antioxidants or signaling molecules? Free Radical. Biol. Med. 36, 838849.
  • Williamson G. and Manach C. (2005) Bioavailability and bioefficacy of polyphenols in humans: II. Review of 93 intervention studies. Am. J. Clin. Nutr. 81, 243S255S.
  • Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 58925901.
  • Yao Z., Drieu K. and Papadopoulos V. (2001) The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from β-amyloid-induced cell death by inhibiting the formation of β-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889, 181190.
  • Yao Z. X., Han Z., Drieu K. and Papadopoulos V. (2004) Ginkgo biloba extract (Egb 761) inhibits β-amyloid production by lowering free cholesterol levels. J. Nutr. Biochem. 15, 749756.
  • Young G. and Conquer J. (2005) Omega-3 fatty acids and neuropsychiatric disorders. Reprod. Nutr. Dev. 45, 128.
  • Zhao Z., Xiang Z., Haroutunian V., Buxbaum J., Stetka B. and Pasinetti G. M. (2006) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer’s disease. Neurobiol. Aging 28, 824830.